Compare $TOVX vs $VTGN | Chartloom

Compare

$TOVX vs $VTGN

Theriva Biologics Inc · Vistagen Therapeutics Inc

TOVX

Theriva Biologics Inc

VTGN

Vistagen Therapeutics Inc

Compare $TOVX vs $VTGN

Comparing Theriva Biologics Inc and Vistagen Therapeutics Inc

TOVXTheriva Biologics Inc

VTGNVistagen Therapeutics Inc

TOVXTheriva Biologics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-16.5%

52W performance

-51.8%

FCF yield

-128.2%

VTGNVistagen Therapeutics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

278.5%

YTD performance

-65.2%

52W performance

-94.1%

FCF yield

-644.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

TOVX

VTGN

Detailed metrics comparison

TOVX

Theriva Biologics Inc

VTGN

Vistagen Therapeutics Inc

Market Cap

TOVX$10M

VTGN$10M

Enterprise Value

TOVX$275K

VTGN$-7M

Price

TOVX$0.22

VTGN$0.24

P/E Ratio

TOVXN/A

VTGNN/A

P/S Ratio

TOVX33.19x

VTGN3.87x

EV/Sales

TOVX0.92x

VTGN-2.92x

EV/EBITDA

TOVX0.00x

VTGN0.00x

P/B Ratio

TOVX0.85x

VTGN0.56x

P/FCF Ratio

TOVXN/A

VTGNN/A

EV/FCF

TOVX-0.02x

VTGN0.12x

PEG Ratio

TOVXN/A

VTGNN/A

Forward P/E (NTM)

TOVXN/A

VTGNN/A

Forward P/S (NTM)

TOVXN/A

VTGNN/A

Revenue (TTM)

TOVX$300K

VTGN$3M

Revenue Growth (YoY)

TOVXN/A

VTGN278.5%

Forward Rev Growth

TOVX20375.2%

VTGN4633.2%

Gross Margin (TTM)

TOVX71.5%

VTGN0.0%

Operating Margin (TTM)

TOVX0.0%

VTGN0.0%

EBITDA Margin (TTM)

TOVX-3940.7%

VTGN-2775.9%

Net Margin (TTM)

TOVX-4376.0%

VTGN-2702.6%

FCF Margin (TTM)

TOVX-4254.7%

VTGN-2493.3%

Net Income (TTM)

TOVX$-13M

VTGN$-68M

FCF (TTM)

TOVX$-13M

VTGN$-62M

EPS (TTM)

TOVX-$0.29

VTGN-$1.57

ROE (TTM)

TOVX-9349.0%

VTGN-15259.0%

ROA (TTM)

TOVX-3269.0%

VTGN-11745.0%

ROIC (TTM)

TOVX-8231.0%

VTGN-15162.0%

Cash

TOVX$11M

VTGN$17M

Debt

TOVX$2M

VTGN$0

Net Cash/Debt

TOVX$10M

VTGN$17M

Current Ratio (TTM)

TOVX1.13x

VTGN3.07x

Quick Ratio (TTM)

TOVX1.09x

VTGN2.84x

Debt/Equity (TTM)

TOVX0.14x

VTGN0.00x

Debt/Assets (TTM)

TOVX0.0%

VTGN0.0%

Interest Coverage (TTM)

TOVXN/A

VTGNN/A

Net Debt/EBITDA (TTM)

TOVX0.00x

VTGN0.00x

Beta

TOVX1.25

VTGN0.49

52W Performance

TOVX-51.8%

VTGN-94.1%

YTD Performance

TOVX-16.5%

VTGN-65.2%

% from 52W High

TOVX-74.8%

VTGN-95.4%

% from 52W Low

TOVX35.6%

VTGN19.2%

Asset Turnover (TTM)

TOVX0.01x

VTGN0.04x

FCF Yield (TTM)

TOVX-128.2%

VTGN-644.0%

Earnings Yield (TTM)

TOVX-131.8%

VTGN-698.0%

Dividend Yield (TTM)

TOVXN/A

VTGNN/A

Rule of 40

TOVX-4,254.7

VTGN-2,214.8

EV/GP/RG

TOVX0.00

VTGNN/A

Ticker research

View TOVX research View VTGN research

Metric	TOVX Theriva Biologics Inc	VTGN Vistagen Therapeutics Inc
Market & Valuation
Market Cap	$10M	$10M
Enterprise Value	$275K	$-7M
Price	$0.22	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	33.19x	3.87x
EV/Sales	0.92x	-2.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.85x	0.56x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.02x	0.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$300K	$3M
Revenue Growth (YoY)	N/A	278.5%
Forward Rev Growth	20375.2%	4633.2%
Profitability
Gross Margin (TTM)	71.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-3940.7%	-2775.9%
Net Margin (TTM)	-4376.0%	-2702.6%
FCF Margin (TTM)	-4254.7%	-2493.3%
Net Income (TTM)	$-13M	$-68M
FCF (TTM)	$-13M	$-62M
EPS (TTM)	-$0.29	-$1.57
ROE (TTM)	-9349.0%	-15259.0%
ROA (TTM)	-3269.0%	-11745.0%
ROIC (TTM)	-8231.0%	-15162.0%
Financial Health
Cash	$11M	$17M
Debt	$2M	$0
Net Cash/Debt	$10M	$17M
Current Ratio (TTM)	1.13x	3.07x
Quick Ratio (TTM)	1.09x	2.84x
Debt/Equity (TTM)	0.14x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.25	0.49
52W Performance	-51.8%	-94.1%
YTD Performance	-16.5%	-65.2%
% from 52W High	-74.8%	-95.4%
% from 52W Low	35.6%	19.2%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.04x
FCF Yield (TTM)	-128.2%	-644.0%
Earnings Yield (TTM)	-131.8%	-698.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4,254.7	-2,214.8
EV/GP/RG	0.00	N/A
Ticker research	View TOVX research	View VTGN research

Valuation

P/S Ratio

VTGN

3.87x

TOVX

33.19x

EV/FCF

TOVX

-0.02x

VTGN

0.12x

Growth & revenue

Revenue Growth TTM

VTGN

278.5%

Forward Revenue Growth

TOVX

20375.2%

VTGN

4633.2%

Profitability & performance

Gross Margin

TOVX

71.5%

VTGN

0.0%

ROE

TOVX

-9349.0%

VTGN

-15259.0%

FCF Yield %

TOVX

-128.2%

VTGN

-644.0%

52-Week Performance

TOVX

-51.8%

VTGN

-94.1%

Detailed metrics comparison

TOVX

Theriva Biologics Inc

VTGN

Vistagen Therapeutics Inc

Market Cap

TOVX$10M

VTGN$10M

Enterprise Value

TOVX$275K

VTGN$-7M

Price

TOVX$0.22

VTGN$0.24

P/E Ratio

TOVXN/A

VTGNN/A

P/S Ratio

TOVX33.19x

VTGN3.87x

EV/Sales

TOVX0.92x

VTGN-2.92x

EV/EBITDA

TOVX0.00x

VTGN0.00x

P/B Ratio

TOVX0.85x

VTGN0.56x

P/FCF Ratio

TOVXN/A

VTGNN/A

EV/FCF

TOVX-0.02x

VTGN0.12x

PEG Ratio

TOVXN/A

VTGNN/A

Forward P/E (NTM)

TOVXN/A

VTGNN/A

Forward P/S (NTM)

TOVXN/A

VTGNN/A

Revenue (TTM)

TOVX$300K

VTGN$3M

Revenue Growth (YoY)

TOVXN/A

VTGN278.5%

Forward Rev Growth

TOVX20375.2%

VTGN4633.2%

Gross Margin (TTM)

TOVX71.5%

VTGN0.0%

Operating Margin (TTM)

TOVX0.0%

VTGN0.0%

EBITDA Margin (TTM)

TOVX-3940.7%

VTGN-2775.9%

Net Margin (TTM)

TOVX-4376.0%

VTGN-2702.6%

FCF Margin (TTM)

TOVX-4254.7%

VTGN-2493.3%

Net Income (TTM)

TOVX$-13M

VTGN$-68M

FCF (TTM)

TOVX$-13M

VTGN$-62M

EPS (TTM)

TOVX-$0.29

VTGN-$1.57

ROE (TTM)

TOVX-9349.0%

VTGN-15259.0%

ROA (TTM)

TOVX-3269.0%

VTGN-11745.0%

ROIC (TTM)

TOVX-8231.0%

VTGN-15162.0%

Cash

TOVX$11M

VTGN$17M

Debt

TOVX$2M

VTGN$0

Net Cash/Debt

TOVX$10M

VTGN$17M

Current Ratio (TTM)

TOVX1.13x

VTGN3.07x

Quick Ratio (TTM)

TOVX1.09x

VTGN2.84x

Debt/Equity (TTM)

TOVX0.14x

VTGN0.00x

Debt/Assets (TTM)

TOVX0.0%

VTGN0.0%

Interest Coverage (TTM)

TOVXN/A

VTGNN/A

Net Debt/EBITDA (TTM)

TOVX0.00x

VTGN0.00x

Beta

TOVX1.25

VTGN0.49

52W Performance

TOVX-51.8%

VTGN-94.1%

YTD Performance

TOVX-16.5%

VTGN-65.2%

% from 52W High

TOVX-74.8%

VTGN-95.4%

% from 52W Low

TOVX35.6%

VTGN19.2%

Asset Turnover (TTM)

TOVX0.01x

VTGN0.04x

FCF Yield (TTM)

TOVX-128.2%

VTGN-644.0%

Earnings Yield (TTM)

TOVX-131.8%

VTGN-698.0%

Dividend Yield (TTM)

TOVXN/A

VTGNN/A

Rule of 40

TOVX-4,254.7

VTGN-2,214.8

EV/GP/RG

TOVX0.00

VTGNN/A

Ticker research

View TOVX research View VTGN research

Metric	TOVX Theriva Biologics Inc	VTGN Vistagen Therapeutics Inc
Market & Valuation
Market Cap	$10M	$10M
Enterprise Value	$275K	$-7M
Price	$0.22	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	33.19x	3.87x
EV/Sales	0.92x	-2.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.85x	0.56x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.02x	0.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$300K	$3M
Revenue Growth (YoY)	N/A	278.5%
Forward Rev Growth	20375.2%	4633.2%
Profitability
Gross Margin (TTM)	71.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-3940.7%	-2775.9%
Net Margin (TTM)	-4376.0%	-2702.6%
FCF Margin (TTM)	-4254.7%	-2493.3%
Net Income (TTM)	$-13M	$-68M
FCF (TTM)	$-13M	$-62M
EPS (TTM)	-$0.29	-$1.57
ROE (TTM)	-9349.0%	-15259.0%
ROA (TTM)	-3269.0%	-11745.0%
ROIC (TTM)	-8231.0%	-15162.0%
Financial Health
Cash	$11M	$17M
Debt	$2M	$0
Net Cash/Debt	$10M	$17M
Current Ratio (TTM)	1.13x	3.07x
Quick Ratio (TTM)	1.09x	2.84x
Debt/Equity (TTM)	0.14x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.25	0.49
52W Performance	-51.8%	-94.1%
YTD Performance	-16.5%	-65.2%
% from 52W High	-74.8%	-95.4%
% from 52W Low	35.6%	19.2%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.04x
FCF Yield (TTM)	-128.2%	-644.0%
Earnings Yield (TTM)	-131.8%	-698.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4,254.7	-2,214.8
EV/GP/RG	0.00	N/A
Ticker research	View TOVX research	View VTGN research